- This article explores the role of technology in shaping pharmaceutical M&A activity, using examples such as Novo Nordisk's acquisition of Catalent.
- We also delve into the rewards and risks that come with these tech-driven acquisitions in the pharmaceutical industry.
- The article highlights how technology can aid in efficient post-merger integration in such M&A deals.
The rising tide of digitization and advanced technology is increasingly being recognized as a crucial catalyst for growth in the pharmaceutical landscape. Where before it merely served as a support framework, we're now witnessing a seismic shift where technology is positioned at the very core of the pharma mergers and acquisitions (M&A) direction, encapsulated in deals such as the Novo Nordisk-Catalent merger.
Promising examples of this evolution include the integration of artificial intelligence (AI) and machine learning into the M&A sphere, revolutionizing how actionable insights are gleaned from large-scale data, how due diligence gets expedited, and how the valuation of assets gets sharpened. AI and machine learning have extended their influence into enabling real-time monitoring of M&A targets and forecasting potential risks, a game-changer for the pharmaceutical sector.
Take, for instance, the $11.4bn Pfizer-Array BioPharma merger in 2019. Pfizer’s due diligence process was exponentially faster, thanks to AI's capability to dissect and synthesize vast banks of clinical and genomic data, revealing previously unexplored uses for Pharma’s drug candidates - a testament to the competitive edge that judicious technology usage provides.
Comments